Phase i dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors

A. Craig Lockhart, Shankar Sundaram, John Sarantopoulos, Monica M. Mita, Andrea Wang-Gillam, Jennifer L. Moseley, Stephanie L. Barber, Alex R. Lane, Claudine Wack, Laurent Kassalow, Jean François Dedieu, Alain C. Mita

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Introduction Cabazitaxel is a second-generation taxane with in vivo activity against taxane-sensitive and -resistant tumor cell lines and tumor xenografts. Cabazitaxel/cisplatin have therapeutic synergism in tumor-bearing mice, providing a rationale for assessing this combination in patients with solid tumors. Methods The primary objectives of this study were to determine dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of a cabazitaxel/cisplatin combined regimen (Part 1) and to assess antitumor activity at the MTD (Part 2). Safety and pharmacokinetics (PK) were also examined. Results Twenty-five patients with advanced solid tumors were enrolled (10 in Part 1; 15 in Part 2). In Part 1, two dose levels were evaluated; the MTD for cabazitaxel/cisplatin (given Q3W) was 15/75 mg/m2. DLTs occurring during Cycle 1 at the maximum administered dose (20/75 mg/m2; acute renal failure and febrile neutropenia) and the MTD (febrile neutropenia and hypersensitivity despite pre-medication) were as expected for taxane/platinum combinations. For the 18 patients treated at the MTD, the most frequent possibly related non-hematologic treatment-emergent adverse events (Grade ≥3) were nausea (16.7 %), fatigue, acute renal failure and decreased appetite (each 11.1 %). Neutropenia was the most frequent treatment-emergent Grade ≥3 hematologic laboratory abnormality at the MTD (77.8 %). The best overall response at the MTD was stable disease, observed in 66.7 % of patients. PK results of the combination did not appear to differ from single-agent administration for each agent. Conclusion Combination treatment with cabazitaxel/cisplatin had a manageable safety profile; no PK interactions were evident. The recommended Phase II dose for this combination is cabazitaxel/cisplatin 15/75 mg/m2 administered every 3 weeks. Antitumor activity findings suggest that further evaluation of this combination in disease-specific trials is warranted.

Original languageEnglish (US)
Pages (from-to)1236-1245
Number of pages10
JournalInvestigational New Drugs
Volume32
Issue number6
DOIs
StatePublished - Dec 1 2014

Keywords

  • Cabazitaxel
  • Cisplatin
  • Dose-escalation
  • Pharmacokinetics
  • Phase I
  • Solid tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase i dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors'. Together they form a unique fingerprint.

  • Cite this

    Lockhart, A. C., Sundaram, S., Sarantopoulos, J., Mita, M. M., Wang-Gillam, A., Moseley, J. L., Barber, S. L., Lane, A. R., Wack, C., Kassalow, L., Dedieu, J. F., & Mita, A. C. (2014). Phase i dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Investigational New Drugs, 32(6), 1236-1245. https://doi.org/10.1007/s10637-014-0145-y